Table 1 The impact of HGF/c-MET pathway in different types of lymphoma
| Type of lymphoma | Outcome | Cellular functions, mechanisms, and clinical consequence | References |
|---|---|---|---|
| B cell-derived | Unfavorable | Enhanced metastasis in vivo | [15] |
| DLBCL | Favorable |
▪ Increase survival of patients ▪ c-MET retained the physiologic growth control ▪ c-MET(+) DLBCL was more proliferated and more responsive to therapy ▪ c-MET directly binds to the pro-apoptotic protein FAS | [18, 23] |
| Primary intestinal DLBCL | Unfavorable | Reduce survival of patients | [19] |
| DLBCL | Unfavorable |
▪ Increase the activities of MEK-MAPK ▪ Increase the activities of PI3K-PKB/AKT and its substrates GSK3 and FOXO3a ▪ Inhibition of fatty acid synthase | [27, 28, 33] |
| PEL | Unfavorable | Required for tumor progression in xenograft model | [37] |
| BL | Unfavorable |
▪ Protection of cells from apoptosis ▪ Activation of MAPK ▪ Induce drug resistance of tumor cells | [39, 40, 64] |
| MALT | Unfavorable | Required for tumor cell proliferation/growth | [41] |
| cHL | Favorable | Increase survival of patients | [42, 43] |
| cHL | Unfavorable | Increase the relapse | [47] |
| ALCL | Unfavorable | Required for tumor progression | [48] |
| NKTCL | Unfavorable | Required for tumor cell proliferation | [49] |
| TLL | Unfavorable | Required for tumor progression | [52, 53, 65] |